Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients
- PMID: 17068084
- DOI: 10.1093/jjco/hyl092
Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients
Abstract
Objective: We analyzed the characteristics of advantages of positron emission tomography (PET) over computed tomography (CT) for N-staging in lung cancer patients.
Methods: Preoperative PET and CT scans were performed for 2057 lymph node stations in 205 patients with peripheral-type lung cancer. The advantages of PET over CT for N-staging were analyzed among lymph node locations and histological subtypes.
Results: The pathological N-stages were N0 in 143 patients, N1 in 31, N2 in 24 and N3 in 7. PET was able to diagnose N0, N2 and N3 diseases more accurately than CT (P=0.03, 0.01 and 0.02, respectively), but there was no significant difference between the two modalities for N1 disease. In the upper mediastinal lymph node stations, both false-negative and false-positive were significantly less frequent with PET than with CT (P=0.001). In the lower mediastinal and supra clavicle lymph nodes, PET showed a lower frequency of false-negative than CT (P=0.04 and 0.003, respectively), but there was no significant difference in the frequency of false-positive between the two modalities. Among histological types, PET could stage adenocarcinoma with less frequent false-negative and squamous cell carcinoma with less frequent false-positive than CT (P=0.02 and 0.005, respectively).
Conclusion: For N-staging, PET was superior to CT for the following: (1) more accurate for N0, N2 and N3 diseases but not for N1; (2) lower frequency of false-positive in the upper mediastinal nodes; and (3) lower frequencies of false-negative in adenocarcinoma and false-positive in squamous cell carcinoma. Recognizing these advantages of PET could make the N-staging of lung cancer more accurate.
Similar articles
-
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Eur J Cardiothorac Surg. 2009. PMID: 19464906 Review.
-
The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23. doi: 10.1016/j.athoracsur.2004.02.067. Ann Thorac Surg. 2004. PMID: 15337041 Clinical Trial.
-
Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.J Thorac Cardiovasc Surg. 2008 Apr;135(4):816-22. doi: 10.1016/j.jtcvs.2007.10.035. J Thorac Cardiovasc Surg. 2008. PMID: 18374761
-
Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.Lung Cancer. 2008 Jul;61(1):35-43. doi: 10.1016/j.lungcan.2007.11.007. Epub 2008 Jan 4. Lung Cancer. 2008. PMID: 18177978
-
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.Eur J Cardiothorac Surg. 2007 Jul;32(1):1-8. doi: 10.1016/j.ejcts.2007.01.075. Epub 2007 Apr 19. Eur J Cardiothorac Surg. 2007. PMID: 17448671
Cited by
-
Mediastinal lymph node staging for lung cancer.Mediastinum. 2019 Aug 19;3:33. doi: 10.21037/med.2019.07.04. eCollection 2019. Mediastinum. 2019. PMID: 35118261 Free PMC article. Review.
-
Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.Surg Today. 2016 Oct;46(10):1146-51. doi: 10.1007/s00595-015-1285-1. Epub 2015 Dec 10. Surg Today. 2016. PMID: 26658716
-
Positron emission tomography in lung cancer.Gen Thorac Cardiovasc Surg. 2009 Apr;57(4):184-91. doi: 10.1007/s11748-008-0371-3. Epub 2009 Apr 15. Gen Thorac Cardiovasc Surg. 2009. PMID: 19367450 Review.